Acute kidney injury (AKI) is a common early complication in patients with hematopoietic SCT (HSCT). However, there are limited data about the incidence and risk factors of AKI in patients with nonmyeloablative HSCT. We conducted a multicenter, retrospective cohort study of 62 patients from three institutions who were treated with similar protocols for nonmyeloablative HSCT. AKI was classified according to the Acute Kidney Injury Network criteria. It was shown that 29% of the patients developed AKI in the first 100 days after nonmyeloablative HSCT. The risk factor at baseline for AKI was incomplete HLA-matched transplant (odds ratio (OR) 3.6; 95% confidence interval (CI) 1.1-13.0). Complications such as acute GVHD, veno-occlusive disease of liver and sepsis were also associated with the development of AKI (OR 12.1; 95% CI 2.4-62.4). AKI was significantly associated with mortality (OR ¼ 4.7; 95% CI 1.9-11.5). We concluded that AKI is a very common complication in patients with nonmyeloablative HSCT, which is associated with incomplete HLAmatched transplant and complications, and has an important impact on the patients' first year of survival.
Introduction
Allogeneic hematopoietic SCT (HSCT) is an increasingly used therapy for many hematological malignancies. Myeloablative (conventional) HSCT involves the use of high-dose chemotherapy-and radiotherapy-conditioning regimens to eradicate the underlying disease. Given the significant morbidity related to myeloablative HSCT, a new procedure has emerged whereby much lower doses of TBI and chemotherapy are used before HSCT. The treatment called nonmyeloablative HSCT relies on the graft-vs-tumor effect of infused donor cells to cure malignancy rather than using chemoradiotherapy. This regimen would be suitable for patients of older age and/or with comorbidities, who are not eligible for myeloablative HSCT. 1, 2 Acute renal failure (ARF) is undoubtedly one of the major organ toxicities in the early period of myeloablative HSCT. If ARF is defined as a doubling of baseline serum creatinine (SCr) in the first 100 days after transplantation, the incidence of ARF varies from 42 to 84%, and ARF seems to independently influence mortality after myeloablative HSCT. [3] [4] [5] [6] The incidence of ARF after nonmyeloablative HSCT is lower than that of myeloablative HSCT, and varies from 33-42%. Moreover, ARF is also an indicator of decreased survival. [7] [8] [9] Recently, several investigators have shown that small changes in kidney function in hospitalized patients are important and have an impact on outcome. [10] [11] [12] Subsequently, the terminology of ARF has been shifted to acute kidney injury (AKI). The Acute Kidney Injury Network (AKIN) criteria provide a uniform definition of AKI and are increasingly used in the literature. 13 These modifications could confer greater sensitivity and specificity to this classification. However, to our knowledge, there are no published data addressing the clinical significance of AKIN classification on the outcome of nonmyeloablative HSCT. The aim of this retrospective study was to investigate the incidence of AKI in adult patients with nonmyeloablative HSCT and its impact on patient survival.
Materials and methods

Patients
From 1 January 2002 to 30 May 2007, adult patients who were treated with similar protocols for nonmyeloablative HSCT at three university teaching hospitals (Zhongda Hospital, Southeast University School of Medicine, Nanjing; Huaian Hospital, Nanjing Medical University, Huaian;
and Zhenjiang First People's Hospital, Jiangsu University, Zhenjiang) were analyzed. Sixty-two cases (33 men and 29 women) participated in this study, including 37 with CML, 19 with AML and 6 with CLL, with a median age of 39.5 years (range: 18-60 years). All patients signed informed consent documents before treatment.
Nonmyeloablative HSCT procedure Normal donor peripheral stem cells were harvested by administering a G-CSF (5 mg/kg/day Â 2/day for 4-5 days), subcutaneously, and 1-2 pheresis procedures (CS3000plus, Baxter, Deerfield, IL, USA). All patients were hospitalized for treatment. The nonmyeloablativeconditioning regimen consisted of fludarabin (30 mg/m 2 / day Â 6 days, À7 to À2 days), BU (4 mg/kg Â 2 days, À6 to À5 days) and CY (350 mg/m 2 /day Â 2 days, À3 to À2 days). Antithymocyte globulin was administered additionally in case of mismatched allogeneic HSCT.
The majority of patients received CsA and mycophenolate mofetil for the prevention of GVHD. CsA was administered intravenously on the day before HSCT (day À1) and was gradually changed to oral intake when the patients could tolerate. The serum drug concentration for CsA was routinely monitored and whole blood levels were maintained at 200-400 ng/ml. Mycophenolate mofetil was administered at 15 mg/kg orally twice a day from days 0 to þ 27 in related recipients, whereas it was administered through to day 100 in unrelated recipients.
Patient monitoring
Data on patient characteristics were collected at the time of HSCT. Gender, age, diagnosis, mismatched transplantation, earlier transplantation and underlying disease were recorded for all patients. The following complications were also recorded (when they occurred within 100 days after transplantation): acute GVHD (aGVHD), veno-occlusive disease (VOD) of liver and sepsis (documented by positive blood cultures). aGVHD 14 and VOD 15 were graded according to the established criteria. A patient was considered positive when he/she suffered from one or more of the complications mentioned above and was assigned a new variable as Complications.
Renal function was assessed by SCr concentration according to the AKIN criteria: grade 0, that is, no AKI; grade 1, renal dysfunction that corresponded to an increase in SCr X0.3 mg per 100 ml (26.4 mmol/l) or an increase to X150-200% (X1.5-to 2-fold) from baseline; grade 2, an increase in SCr to 4200-300% (42-to 3-fold) from baseline; grade 3, an increase in SCr to 4300% (43-fold) from baseline or SCr X4.0 mg per 100 ml (354 mmol/l), with an acute increase of at least 0.5 mg per 100 ml (44 mmol/l). AKI patients of grade 2 and grade 3 were considered as having severe renal dysfunction. The estimated glomerular filtration rate (GFR) was calculated by the MDRD equation (GFR (ml/min per 1.73 m 
Statistical analysis
Continuous variables are displayed as the median, with range in parentheses. Comparisons of variables between the various grades of AKI were facilitated using either analysis of variance or the Kruskal-Wallis H test (where appropriate). Those parameters reaching a univariable significance level of Pp0.1 were assessed for significance using multiple logistic regressions. Kaplan-Meier survival curves were drawn for 1-year OS. The curves were compared using the log-rank test. All P-values were two-sided, and a value of o0.05 was considered statistically significant. All analyses were carried out using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient baseline characteristics
The baseline characteristics of the 62 patients are shown in Table 1 . Among them, only one patient had hypertension, three had chronic liver disease and one had diabetes. All of them received HSCT for the first time. The patients received hematopoietic cell grafts from HLA identical (n ¼ 44) or five of six HLA-matched (incomplete HLA matched) (n ¼ 18) donors. Fifty-three patients received their graft from their sibling and nine from an unrelated donor.
Changes in renal function and risk factors
An analysis of the entire group showed a rise in SCr from 67 (43-105) mmol/l to 77 (44-270) mmol/l (Po0.001), and a decrease in calculated GFR from 108 (68-146) ml/min per (Figure 1 ). It showed a downward trend in the baseline GFR of patients from AKI grade 0 to grade 3, although it did not reach statistical difference among the groups (P40.5).
Risk factor at baseline for AKI was incomplete HLAmatched transplant (P ¼ 0.020) in univariate analysis for all the variables. There was no statistical difference in age, gender, underlying disease, type of transplant or in SCr and estimated GFR at the time of transplantation among the groups ( Table 2 ). The complications of aGVHD, VOD and sepsis occurring in the first 100 days were also associated with AKI (P ¼ 0.003, 0.008 and 0.007, respectively, Table 2 ). Forward stepwise multivariate regression analysis showed that only Complications (a patient was considered positive when he/she suffered from one or more complications mentioned above) and incomplete HLA-matched transplant were significantly associated with AKI (odds ratio (OR) 12.1, 95% confidence interval (CI) 2.4-62.4, P ¼ 0.003; OR 3.6 95%, CI 1.1-13.0, P ¼ 0.046, respectively) (Table 3) , whereas neither aGVHD I or II-IV, nor VOD nor sepsis was associated with AKI solely (P40.05).
Association between AKI and mortality After 1 year, 45 patients (72.6%) were still alive and 17 patients (27.4%) had died. The causes of death were relapse (5 of 17, 29.4%), VOD (2 of 17, 11.8%), sepsis (7 of 17, 41.2%) and aGVHD (3 of 17, 17.6%). Mortality rate increased significantly from AKI grade 0 (no AKI) to AKI grade 3 (grade 0, 13.6%; grade 1, 54.5%; and grades 2-3, Table 2 Baseline characteristics, complications, and outcome when categorized by acute kidney injury after nonmyeloablative HSCT 71.4%; P ¼ 0.001) ( Table 2) . Kaplan-Meier survival curves (Figure 2 ) of the three categories of AKI (grade 0, grade 1 and grades 2-3) showed a significant difference in 1-year survival, with the best survival in patients without AKI (grade 0) and the worst survival in patients with AKI grades 2-3 (log-rank test, Po0.001). The forward stepwise multivariate regression analysis of AKI (AKI grades 1, 2 and 3 were combined for the regression analysis) against mortality within 1 year after nonmyeloablative HSCT is shown in Table 4 . The logistic regression models were adjusted for potential confounders. The unadjusted odds of association of AKI with mortality were 4.7. After controlling for various demographics, HSCT and complications, the odds of association of AKI with mortality decreased modestly (OR ¼ 3.3; 95% CI 1.0-11.1).
Discussion
Allo-SCT has been proven to be an effective means of treatment for a variety of malignant and nonmalignant conditions. Owing to organ toxicity and the high mortality of myeloablative HCT, the procedure is generally only available for younger patients without comorbid disease. A recently developed procedure, nonmyeloablative allogeneic HSCT (also known as 'mini-allo' transplant), has been used mainly in elderly individuals and in individuals with organ dysfunction. This procedure uses a low-dose conditioning regimen and is not designed to eradicate malignant cells but rather to provide sufficient immunosuppression to allow the engraftment of HSCT. The hypothesis is that engrafted hematopoietic stem cells will cause an immunological graftvs-tumor response that destroys tumor cells. 1 CML and CLL are the most sensitive to graft-vs-tumor effects, with AML being moderately sensitive. In this study, patients with CML, CLL or AML were treated with nonmyeloablative HSCT to reduce the toxicity associated with allogeneic hematopoietic transplantation.
Acute kidney injury is now understood to be a common complication after HSCT. In an earlier small study of 26 recipients of nonmyeloablative HSCT, 17 we found that 19% of patients developed AKI grades 2-3. In this multicenter study, 12.9% of patients developed AKI grades 2-3. This is much less significant compared with those reported in myeloablative HSCT (49.6%) and nonmyeloablative HSCT (32.7%) by Kersting et al. 6, 7 The incidence is also less than that reported by Parikh et al.
9 (myeloablative HSCT ¼ 73%; nonmyeloablative HSCT ¼ 47%). Controlling for clinical variables, Parikh et al. 9 found that the risk of developing renal failure was nearly fivefold less for nonmyeloablative transplantation compared with that for myeloablative regimens. The difference in incidence may be because of conditioning regimens and patients' baseline characteristics. Compared with myeloablative regimens, nonmyeloablative transplants are associated with regimen-related toxicity reduction despite older age and more comorbidities. 18, 19 In the study of nonmyeloablative HSCT, median age was 56.5 years, baseline GFR was 82 (35-187) ml/min per 1.73 m 2 , and preexisting autologous HSCT, hypertension and vascular disease accounted for 39.3, 37.3 and 11.3%, respectively. 7 Obviously, the patients in this study were younger (median age: 39.5 years), their baseline renal functions were better (108 ml/min per 1.73 m 2 ) and they had less comorbid conditions (only one had hypertension and no one had autologous HSCT or vascular disease). Therefore, age, baseline GFR and preexisting disease might be identified as the predisposing factors for AKI in patients after HSCT.
More recently, ARF was often referred to as 'acute kidney injury' (AKI) in recognition of the potential clinical importance of small changes in kidney function. In a consecutive sample of 19 982 adults admitted to an urban medical center, Chertow et al. 11 found that patients with an increase in SCr of just 0.3-0.4 mg per 100 ml had a 70% higher multivariable-adjusted odds of death than did patients with little or no change in SCr. Other investigators have reported similar findings in patients with congestive heart failure. 12, 20 A more recent classification for AKI has been proposed by the Acute Kidney Injury Network (AKIN). In our study, the incidence of AKI after nonmyeloablative HSCT was 29.0% and that of AKI grade 1 was 17.7%. The mortality at 1 year was more than fourfold high in patients with AKI grade 1 compared with that in patients without AKI (grade 0). The patients with AKI had more than fourfold higher odds of mortality. The odds of mortality in AKI patients were still higher (3.3-fold), even when adjusted for other variables, although it did not reach statistical significance (P ¼ 0.054). Further research with a large sample size is needed to determine the relationship between AKI and survival. In this cohort study, AKI was associated with complications (aGVHD, sepsis and VOD). These factors may act solely or collectively to cause renal failure. 7, 8 aGVHD may affect the kidney through cytokine-and immune-related injury, including glomerular deposits, leading to nephrotic syndrome and tubulitis. 21 However, other studies showed that dehydration because of diarrhea in patients with aGVHD II-IV is most likely to be the cause of AKI. 4, 7 In the setting of sepsis, cytokine-induced renal vasoconstriction, cytokine-induced intrarenal inflammation and C 0 -mediated renal injury contribute to renal failure. Agents used to treat bacteremia and sepsis may also contribute to nephrotoxicity in this setting. Clinically, VOD begins as a fluid-retentive state with low urinary sodium that leads to peripheral edema and weight gain within the first few days after transplantation, mimicking the hepatorenal syndrome. 15 Interestingly, we found that incomplete HLA-matched transplant had a risk of developing AKI. An analysis of a much larger population of patients with leukemia showed that the relative risk of treatment failure and the overall risk of transplant-related mortality were significantly higher for patients who received a 1-or 2-Ag-mismatched transplant compared with those for patients who received an HLA-identical sibling-donor transplant. 22 In this study, the mortality rate of patients within 1 year was found to be 27.4%, which was lower than that reported earlier. 5, 8 Therefore, we suggested that nonmyeloablative HSCT might be a safe therapy for younger patients and for elderly patients without baseline organ dysfunction.
In summary, our study indicates that the AKIN criteria enabled us to identify 29% of patients with various degrees of acute renal dysfunction during the first 100 days after nonmyeloablative HSCT. Incomplete HLA-matched transplant and complications increased the risk of AKI. AKI may be an indicator ofr decreased survival. Further studies will be required to evaluate long-term AKI after nonmyeloablative HSCT.
